Skip to main content Skip to navigation
V450 Mouse Anti-Human FMC7
Product Details
Down Arrow Up Arrow

BD Horizon™
Mouse IgM, κ
Human B-lymphoblastoid cell line HRIK
Flow cytometry
100 μg/mL
5 μL

644493 Rev. 1
Antibody Details
Down Arrow Up Arrow

Clone FMC7 is derived from the fusion of mouse P3-NS1-1-AG4-1 myeloma cells with spleen cells from BALB/c mice immunized with human B-lymphoblastoid cell line HRIK.

FMC7 recognizes a 105-kDa membrane glycoprotein expressed on a subset of B lymphocytes.

644493 Rev. 1
Format Details
Down Arrow Up Arrow
BD Horizon™ V450 Dye is part of the BD Horizon™ violet family of dyes. This is a small organic fluorochrome with an excitation maximum (Ex Max) at 405-nm and an emission maximum (Em Max) at 450-nm. BD Horizon™ V450, driven by BD innovation, is designed to be excited by the violet laser (405 nm) and detected using an optical filter centered near 450-nm (e.g., a 450/50-nm bandpass filter). The dye can be excited by the UV (355-nm) laser resulting in cross-laser excitation and spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
Violet 405 nm
405 nm
450 nm
644493 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (10)

  1. Bloem AC, Chand MA, Dollekamp I, Rijkers GT. Functional properties of human B cell subpopulations defined by monoclonal antibodies HB4 and FMC7. J Immunol. 1988; 140:768-773. (Biology).
  2. Brooks DA, Beckman IG, Bradley J, McNamara PJ, Thomas ME, Zola H. Human lymphocyte markers defined by antibodies derived from somatic cell hybrids, IV, A monoclonal antibody reacting specifically with a subpopulation of human B lymphocytes. J Immunol. 1981; 126:1373-1377. (Biology).
  3. Catovsky D, Brooks CD, Bradley J, Zola H. Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7. Blood. 1981; 58:406-408. (Biology).
  4. Ferro LM, Zola H. Modulation of expression of the antigen identified by FMC7 upon human Blymphocyte activation: evidence for differences between activation in vivo and in vitro. Immunology. 1990; 69:373-378. (Biology).
  5. Geisler CH, Larsen JK, E HN, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood. 1991; 78:1795-1802. (Biology).
  6. Huh YO, Pugh WC, Kantarjian HM, et al. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol. 1994; 101:283-289. (Biology).
  7. Kilo MN, Dorfman DM. The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am J Clin Pathol . 1996; 105:451-457. (Biology).
  8. Rijkers GT, Dollekamp I, Zegers BJM. Evidence that FMC7 is a human B cell differentiation antigen. Immunol Lett. 1990; 24:261-264. (Biology).
  9. Staal F, Rozemuller E, Gmelig Meyling FHJ, Bloem AC. Knapp W, Dörken B, Gilks WR, et al, ed. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:139-140.
  10. Zola H, Neoh SH, Potter A, Melo JV, De Oliveria MSP, Catovsky D. Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules. Disease Markers. 1987; 5:227-235. (Biology).
View All (10) View Less
644493 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. 


Although not required, these products are manufactured in accordance with Good Manufacturing Practices.